Northland Capital Markets Starts Oncternal Therapeutics (ONCT) at Outperform
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
Northland Capital Markets initiates coverage on Oncternal Therapeutics (NASDAQ: ONCT) with a Outperform rating and a price target of $21.00.
Shares of Oncternal Therapeutics closed at $7.20 yesterday.
You May Also Be Interested In
- UPDATE: Wolfe Research Starts Duck Creek Technologies (DCT) at Outperform
- UPDATE: Wolfe Research Starts ServiceNow (NOW) at Outperform
- UPDATE: Wolfe Research Starts Docusign Inc. (DOCU) at Outperform